These results suggest that IL-33 administration stimulates circulating inflammatory KLRG1hi ILC2s, blocks type 1 immunity against multiple myeloma cells, and contraindicates the therapeutic dispensation of IL-33 to myeloma subjects. This evidence concerns the gene IL33 and AL amyloidosis.